Université de Lyon, VetAgro Sup, Service de cancérologie, UR ICE, Marcy l'Etoile, France.
ONCOnseil-Unité d'expertise en oncologie vétérinaire, Toulouse, France.
Vet Comp Oncol. 2024 Sep;22(3):437-446. doi: 10.1111/vco.12995. Epub 2024 Jul 15.
Electrochemotherapy (ECT) with intravenous (IV) and/or intratumoral (IT) bleomycin has shown considerable efficacy in the treatment of non-resectable feline cutaneous squamous cell carcinoma (cSCC), boasting response rates of up to 95%, but other chemotherapy protocols have not yet been investigated. The objective of this prospective multicentre study was to compare the overall response rate (ORR) and progression-free interval (PFI) between cats with cSCC treated with ECT using IT and IV carboplatin (IV + IT), IV carboplatin (IV) or IV bleomycin (IV). A total of 44 cats with unresectable cSCC across three centres were enrolled and treated with ECT using carboplatin IV + IT (n = 10), carboplatin IV (n = 11) or bleomycin IV (n = 23). Treatment response according to RECIST criteria was recorded at 2 and 4 weeks post-treatment, and patients were followed until disease progression and/or death. All three groups were comparable regarding age, sex, weight, and lesion size. Adverse events were generally mild, localised and similar between groups. ORRs were 90.0% (carboplatin IV + IT), 90.9% (carboplatin IV) and 95.6% (bleomycin IV) and were not significantly different (p = 0.79). Median PFI was not reached for carboplatin IV + IT or carboplatin IV and was 566 days for bleomycin IV, with no significant difference between the three groups (p = 0.81). This study suggests that ECT using IV or IV + IT carboplatin is a reasonable alternative therapeutic option for managing cSCC, and further studies are warranted to compare outcomes between treatment protocols.
电化学疗法（ECT）联合静脉（IV）和/或肿瘤内（IT）博来霉素治疗不可切除的猫皮肤鳞状细胞癌（cSCC）已显示出相当大的疗效，反应率高达 95%，但其他化疗方案尚未进行研究。本前瞻性多中心研究的目的是比较使用 IT 和 IV 卡铂（IV + IT）、IV 卡铂（IV）或 IV 博来霉素（IV）治疗 cSCC 的猫的总缓解率（ORR）和无进展间隔（PFI）。共有三家中心的 44 只不可切除的 cSCC 猫入组并接受 ECT 治疗，其中使用卡铂 IV + IT（n = 10）、卡铂 IV（n = 11）或 IV 博来霉素（n = 23）。根据 RECIST 标准记录治疗后 2 和 4 周的治疗反应，随访至疾病进展和/或死亡。三组在年龄、性别、体重和病变大小方面具有可比性。不良事件通常轻微、局限且在组间相似。ORR 分别为 90.0%（卡铂 IV + IT）、90.9%（卡铂 IV）和 95.6%（博来霉素 IV），无统计学差异（p = 0.79）。卡铂 IV + IT 或卡铂 IV 的中位 PFI 未达到，博来霉素 IV 的 PFI 为 566 天，三组之间无显著差异（p = 0.81）。本研究表明，使用 IV 或 IV + IT 卡铂的 ECT 是治疗 cSCC 的一种合理的替代治疗选择，需要进一步的研究来比较治疗方案之间的结果。
